Featured Batteries

Computerized tests are expertly configured into fit-for-purpose batteries to sensitively assess cognitive function in many indications across all phases of clinical research.

Accurately establish the cognitive effects of investigational and marketed products using Cogstate’s customizable batteries.

Detect and monitor the core cognitive deficits associated with key neurodegenerative and psychiatric disorders including Alzheimer’s disease, brain injury, depression, Multiple Sclerosis and Schizophrenia.

The scientific rationale and support for their validity, reliability and sensitivity to drug effects in clinical trials has been detailed in hundreds of peer-reviewed scientific publications.

Watch the 2 minute overview of the Cogstate Brief Battery

Cogstate Batteries

Cogstate Brief Battery

A rapid and reliable cognitive screening assessment across indications and phases of development.

The Cogstate Brief Battery™ has been used extensively as a rapid and reliable screening assessment in a range of clinical indications, including Alzheimer’s Disease, depression, schizophrenia, AIDS, dementia complex and as a measure of cognitive decline following a mild traumatic brain injury or suspected concussive episode. The Cogstate Brief Battery has also been used widely in the context of measuring cognitive dysfunction relative to healthy groups in both pediatric and adult populations.

The Cogstate Brief Battery provides a measure of four core cognitive domains: processing speed, attention, visual learning and working memory. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in clinical trials and maintain excellent reliability across repeated testing and cross-sectional research designs. This battery maintains excellent psychometric properties in relation to test-retest reliability. The criterion and construct validity of each test for cognitive impairment as well as the sensitivity of these tests to change in cognition has been demonstrated in the scientific literature, and each test has also been shown to be valid for use in different cultures and language groups.

Cogstate Tests

  • Detection Test
  • Identification Test
  • One Card Learning Test
  • One Back Test

Battery Details

Length:Approx. 12-15 minutes
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV; general cognitive screening battery
Culture and Language Neutral:Yes

Key References

Lim, Y. Y., Ellis, K. A., Harrington, K., Ames, D., Martins, R. N., Masters, C. L., … Group, T. A. R. (2012). Use of the CogState Brief Battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol, 34(4), 345–358.

Lim, Y. Y., Jaeger, J., Harrington, K., Ashwood, T., Ellis, K. a, Stöffler, A., … Maruff, P. (2013). Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer’s Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). Archives of clinical neuropsychology :doi:10.1093/arclin/act021

Maruff, P., Lim, Y. Y., Darby, D., Ellis, K. A., Pietrzak, R. H., Snyder P. J., Bush, A. I., Szoeke, C., Schembri, A., Ames, D., Masters, C. L., & the AIBL Research Group (2013) Clinical utility of the Cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease. BMC Pharmacology & Toxicology, 1:30

Fredrickson, J., Maruff, P., Woodward, M., Moore, L., Fredrickson, A., Sach, J., Darby, D. (2010) Evaluation of the Usability of a Brief Computerized Cognitive Screening Test in Older People for Epidemiological Studies. Neuroepidemiology, 34: 65-75.

Louey, A. G., Cromer, J. A., Schembri, A. J., Darby, D. G., Maruff, P., Makdissi, M., & Mccrory, P. (2014). Detecting cognitive impairment after concussion: sensitivity of change from baseline and normative data methods using the CogSport/Axon cognitive test battery. Archives of Clinical Neuropsychology, 29(5), 432-441. doi: 10.1093/arclin/acu020

Cogstate Schizophrenia Battery

Assess cognitive function in subjects with schizophrenia in both the acute and chronic stages.

Cogstate’s computerised battery of rapid, reliable, simple and sensitive tests measures the cognitive domains affected by schizophrenia: processing speed, attention, verbal and visual learning, working memory, visual motor function, executive function and social cognition.

Tests can be grouped to match the cognitive domains recommended by the MATRICS group, or smaller groups of tests can be assembled to measure more specific domains. For each test, the construct validity for cognitive impairment in schizophrenia, as well as the sensitivity to change in cognition in schizophrenia has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical populations and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.

Cogstate Tests

  • Detection Test
  • Identification Test
  • One Card Learning Test
  • One Back Test
  • Two Back Test
  • International Shopping List Test
  • Social-Emotional Cognition Test
  • Groton Maze Learning Test

Battery Details

Length:Approx. 35 minutes
(if all tests in the battery are selected*)
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Key References

Bartzokis, G., Lu, P. H., Amar, C. P., Raven, E. P., Detore, N. R., Altshuler, L. L., …  Nuechterlein, K. H. (2011). Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophrenia Research, 132(1), 35-41. doi: 10.1016/j.schres.2011.06.029

Lieberman, J. A., Dunbar, G., Segreti, A. C., Girgis, R. R.,  Seoane, F., Beaver, J. S.,  Duan, N. & Hosford, D. A., (2013) A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia. Neuropsychopharmacology, 38, 968-975.

Pietrzak, R. H., Snyder, P. , J.Maruff, P. (2010)  Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Human Psychopharmacology, 25, 353-358.

Preskorn, S. H., Gawryl, M., Dgetluck, N., Palfreyman, M., Bauer, L. O., & Hilt, D. C. (2014). Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. Journal of Psychiatric Practice, 20(1), 12–24. doi:10.1097/01.pra.0000442935.15833.c5

Riedel, M., Schmitz, M., Kåre, P., Ferrannini, L., Franco, M. A., Alfano, V., & Dencker, E. (2015). Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance , sedation and patient satisfaction in patients with schizophrenia : A randomised , double-blind , crossover study ( eXtRa ). Schizophrenia Research. doi:10.1016/j.schres.2014.12.027

Cogstate Pre-Clinical Alzheimer’s Battery

Assess cognitive function in subjects with pre-clinical Alzheimer’s disease.

Cogstate’s computerized battery of rapid, reliable, simple and sensitive tests measure the cognitive domains affected by mild cognitive impairment and pre-clinical AD: processing speed, attention, visual learning and working memory.

The construct validity of each test for cognitive impairment in pre-clinical AD as well as the sensitivity of these tests to change in cognition has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.

Cogstate Tests

  • Detection Test
  • Identification Test
  • One Card Learning Test
  • One Back Test

Battery Details

Length:Between 5-15 minutes
(depending on the number of tests included in the battery*)
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Key References

Lim, Y. Y., Maruff, P., Pietrzak, R. H., Ellis, K. A., Darby, D., Ames, D., … Rowe, C. C. (2014). Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer’s disease. Alzheimer’s & Dementia, 10(6), 743-751. doi: http://dx.doi.org/10.1016/j.jalz.2013.11.005

Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Ames, D., Ellis, K. A., Harrington, K., … Maruff, P. (2014). APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. Neurobiology of Aging, 11. doi: 10.1016/j.neurobiolaging.2014.12.008

Lim, Y. Y., Ellis, K. A., Harrington, K., Pietrzak, R. H., Gale, J., Ames, D., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G., Szoeke, C., Villemagne, V. L., Maruff P. (2013) Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer’s disease? Journal of Alzheimer’s Disease: 33 (4); 1167-76

Lim, Y. Y., Maruff, P., Pietrzak, R. H., Ames, D., Ellis, K. a, Harrington, K., … Rowe, C. C. (2014). Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain : a journal of neurology, 137(Pt 1), 221–31. doi:10.1093/brain/awt286

Lim, Y. Y., Villemangne, V. L., Laws, S. M., Pietrzak, R. H., Snyder, P. J., Ames, D., … Maruff, P. (2014). APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer’s disease. Molecular Psychiatry. doi: 10.1038/mp.2014.123

Cogstate Alzheimer's Battery

Assess cognitive function in adults with mild cognitive impairment (MCI) and clinically-diagnosed Alzheimer’s disease (AD).

Cogstate’s computerized battery of rapid, reliable, simple and sensitive tasks measures the cognitive domains affected by MCI and AD, namely processing speed, attention, verbal and visual learning, working memory, visual motor and executive function.

The construct validity of each test for cognitive impairment in MCI and AD as well as the sensitivity of these tests to change in cognition has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.

Cogstate Tests

  • Detection Test
  • Identification Test
  • One Card Learning Test
  • One Back Test
  • International Shopping List Test
  • International Shopping List Test – Delayed Recall
  • Continuous Paired Associate Learning Test
  • Groton Maze Learning Test

Battery Details

Length:Between 5-30 minutes
(depending on the number of tests included in the battery*)
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Key References

Darby, D. G., Pietrzak, R. H., Fredrickson, J., Woodward, M., Moore, L., Fredrickson, A., … Maruff, P. (2012). Intraindividual cognitive decline using a brief computerized cognitive screening test. Alzheimer’s and Dementia, 8(2), 95–104. doi:10.1016/j.jalz.2010.12.009

De Jager, C. a, Schrijnemaekers, A.-C. M. C., Honey, T. E. M., & Budge, M. M. (2009). Detection of MCI in the clinic: evaluation of the sensitivity and specificity of a computerised test battery, the Hopkins Verbal Learning Test and the MMSE. Age and ageing, 38(4), 455–60. doi:10.1093/ageing/afp068

Hammers, D., Spurgeon, E., Ryan, K., Persad, C., Barbas, N., Heidebrink, J., … Giordani, B. (2012). Validity of a brief computerized cognitive screening test in dementia. J Geriatric Psychiatry Neurology, 25(2), 89–99. doi:10.1177/0891988712447894.

Hammers, D., Spurgeon, E., Ryan, K., Persad, C., Heidebrink, J., Barbas, N., Albin, R., Frey, K., Darby , D., and Giordani, B. (2011) Reliability of Repeated Cognitive Assessment of Dementia Using a Brief Computerized Battery. American Journal of Alzheimer’s Disease and Other Dementia’s: 26 (4) 326-333.

Lim, Y. Y., Ellis, K. A., Harrington, K., Ames, D., Martins, R. N., Masters, C. L., … Group, T. A. R. (2012). Use of the CogState Brief Battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Journal of Clinical and Experimental Neuropsychology, 34(4), 345–358. doi:10.1080/13803395.2011.643227

Lim, Y. Y., Ellis, K. A., Pietrzak, R. H., Ames, D., Darby, D., Harrington, K., … the AIBL Research Group, F. (2012). Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology, 79(16), 1645–1652. doi:10.1212/WNL.0b013e31826e9ae6

Lim, Y. Y., Ellis, K. A., Ames, D., Darby, D., Harrington, K., Martins, R. N., … Group, A. R. (2012). Aβ amyloid, cognition, and APOE genotype in healthy older adults. Alzheimers Dementia. doi:10.1016/j.jalz.2012.07.004

Lim, Y. Y., Jaeger, J., Harrington, K., Ashwood, T., Ellis, K. A., Stoffler, A., … Maruff, P. (2013). Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer’s disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). Archives of Clinical Neuropsychology, 28(4), 320-330. doi: 10.1093/arclin/act021

Maruff, P.,  Lim, Y. Y., Darby, D., Ellis, K. A., Pietrzak, R. H., Snyder P. J., Bush, A. I., Szoeke, C., Schembri, A., Ames, D., Masters, C. L., & the AIBL Research Group (2013). Clinical utility of the Cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease. BMC Pharmacology & Toxicology, 1:30

Cogstate Brain Injury Battery

Assess cognitive function in subjects with concussion and Traumatic Brain Injury (TBI).

Cogstate’s computerized battery of rapid, reliable, simple and sensitive tests measure the cognitive domains affected by concussion and TBI, namely processing speed, attention, visual learning, working memory, visual motor function and executive function.

The construct validity of each test for cognitive impairment in concussion and TBI as well as the sensitivity of these tests to change in cognition has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in professional athletes, different cultures and different language groups, with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests maintains excellent reliability across repeated testing and cross-sectional research designs.

Cogstate Tests

  • Detection Test
  • Identification Test
  • One Card Learning Test
  • One Back Test
  • Groton Maze Learning Test

Battery Details

Length:Between 5-20 minutes
(depending on the number of tests included in the battery*)
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Key References

Cole, W. R., Arrieux, J. P., Schwab, K., Ivins, B. J., Qashu, F. M., and Lewis,  S. C. (2013). Test–Retest Reliability of Four Computerized Neurocognitive Assessment Tools in an Active Duty Military Population.  Archives of Clinical Neuropsychology: 28 (7), 732 – 42.

Eckner, J.T , Kutcher, J. S.,  Richardson, J. K., (2011). Between-Seasons Test-Retest Reliability of Clinically Measured  Reaction Time in National Collegiate Athletic  Association Division I Athletes. Journal of Athletic Training; 46 (4); 409-414.

Eckner, J. T.,  Kutcher, J. S.,  Richardson J. K., (2011). Effect of Concussion on Clinically Measured Reaction Time in 9 NCAA Division I Collegiate Athletes: A Preliminary Study. Physical Medicine and Rehabilitation, 3, 212-218.

Louey, A. G., Cromer, J. A., Schembri, A. J., Darby, D. G., Maruff, P., Makdissi, M., & Mccrory, P. (2014). Detecting cognitive impairment after concussion: sensitivity of change from baseline and normative data methods using the CogSport/Axon cognitive test battery. Archives of Clinical Neuropsychology, 29(5), 432-441. doi: 10.1093/arclin/acu020

Cogstate Depression Battery

Assess cognitive function in subjects with clinically diagnosed Major Depressive Disorder (MDD).

Cogstate’s computerized battery of rapid, reliable, simple and sensitive tests measure the cognitive domains affected by MDD: processing speed, attention, visual learning, working memory, visual motor function and executive function.

The construct validity of each test for cognitive impairment in MDD as well as the sensitivity of these test to change in cognition has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.

Cogstate Tests

  • Detection Test
  • Identification Test
  • One Card Learning Test
  • One Back Test
  • Groton Maze Learning Test

Battery Details

Length:Between 5-20 minutes
(depending on the number of tests included in the battery*)
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Key References

McIntyre, R. S., Lophaven, S., Olsen, C. K. (2014). A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology, 17(10), 1557-1567. doi: 10.1017/S1461145714000546.

Olver, J. S., Ignatiadis, S., Maruff, P., Burrows, G. D., and Norman, T. R., (2008) Quetiapine augmentation in depressed patients with partial response to antidepressants. Human  Psychopharmacology Clinical and Experimental; 23: 653–660.

Shiroma, P.R., Albott, C.S., Johns, B., Thuras, P., Wels, J., & Lim, K. O. (2014). Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology, 17(11), 1805-1813. doi: 10.1017/S1461145714001011

Yoshida, T., Ishikawa, M., Niitsu, T., Nakazato, M., Watanabe, H., Shiraishi, T., … Hashimoto, K. (2012). Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One, 7(8). doi: 10.1371/journal.pone.0042676

Cogstate Multiple Sclerosis Battery

Assess cognitive function in subjects with Multiple Sclerosis (MS).

Cogstate’s computerized battery of rapid, reliable, simple and sensitive tests measure the cognitive domains affected by MS: processing speed, attention, verbal and visual learning, working memory, visual motor function and executive function.

Each cognitive test has been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.

Cogstate Tests

  • Detection Test
  • Identification Test
  • One Card Learning Test
  • One Back Test
  • Two Back Test
  • International Shopping List Test
  • Groton Maze Learning Test

Battery Details

Length:Between 5-40 minutes
(depending on the number of tests included in the battery*)
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Cogstate Early Phase Battery

Demonstrate the cognitive safety profile of compounds in early phase clinical trials.

The Cogstate early phase battery has been used extensively in Phase I research to determine the extent to which treatment with different doses of experimental compounds is associated with changes in cognitive function. Sponsors can get an earlier understanding of how the safety profile of their compound compares to the standard of care or to detect cognitive decline caused by a compound or dosing level before costly late phase trials are initiated.

Tight timelines with strict measurement regimens are a hallmark of early phase research. To address this, the Cogstate early phase battery is brief and has demonstrated that repeated measurement does not give rise to practice effects.  Hence the Cogstate battery can be applied repeatedly in the same individuals under different treatment conditions and the data generated can be used in pharmacokinetic/pharmacodynamics models, or in comparisons between treatment conditions to guide decisions about the safety or efficacy of the medicines studied.  Because the tests in the Cogstate early phase battery have also been used extensively in clinical studies, there exists a large database of treatment effects and their magnitudes that can be used to assist researchers in interpretation of their results.  Furthermore data generated in early phase studies can be considered against performance on the same tests in Phase II and Phase III studies of neurological and psychiatric disorders.

Cogstate’s computerized early phase battery measures the cognitive domains of processing speed, attention, visual learning and executive function. The construct validity of each test for cognitive impairment as well as the sensitivity of these tests to change in cognition has been demonstrated in the scientific literature, and each test has also been shown to be valid for use in different cultures and language groups.

Cogstate Tests

  • Detection Test
  • Identification Test
  • One Card Learning Test
  • Groton Maze Learning Test

Battery Details

Length:Approx. 15 minutes
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I
Culture and Language Neutral:Yes

Key References

Collie, A., Maruff, P., Snyder, P. J., Darekar, A., & Huggins, J. P. (2006). Cognitive testing in early phase clinical trials: Outcome according to adverse event profile in a Phase I study. Human Psychopharmacology, 21, 481-488.

Collie, A., Darkar, A., Weissgerber, G., Toh, M. K., Snyder, P. J., Maruff, P., & Huggins, J. P. (2007). Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study. Contemporary Clinical Trials, 28, 391-400.